

**Anti-VEGF Reference Antibody (BioMab patent anti-VEGF)
Recombinant Antibody
Catalog # APR11070****Specification**

Anti-VEGF Reference Antibody (BioMab patent anti-VEGF) - Product Information

| | |
|-------------------|----------------------------|
| Application | FC, Kinetics, Animal Model |
| Primary Accession | P15692 |
| Reactivity | Human |
| Clonality | Monoclonal |
| Isotype | IgG1 |
| Calculated MW | 145 KDa |

Anti-VEGF Reference Antibody (BioMab patent anti-VEGF) - Additional Information**Target/Specificity**
VEGF**Endotoxin**
< 0.001EU/ µg,determined by LAL method.**Conjugation**
Unconjugated**Expression system**
CHO Cell**Format**
Purified monoclonal antibody supplied in PBS, pH6.0, without preservative.This antibody is purified through a protein A column.**Anti-VEGF Reference Antibody (BioMab patent anti-VEGF) - Protein Information****Name** VEGFA**Synonyms** VEGF**Function**
[N-VEGF]: Participates in the induction of key genes involved in the response to hypoxia and in the induction of angiogenesis such as HIF1A (PubMed:35455969). Involved in protecting cells from hypoxia- mediated cell death (By similarity).**Cellular Location**
[N-VEGF]: Cytoplasm. Nucleus. Note=Cytoplasmic in normoxic conditions and localizes to the nucleus under hypoxic conditions [Isoform L-VEGF189]: Endoplasmic reticulum. Golgi apparatus. Secreted, extracellular space, extracellular matrix [Isoform VEGF165]: Secreted


Tissue Location

Higher expression in pituitary tumors than the pituitary gland. [Isoform VEGF165]: Widely expressed. [Isoform VEGF206]: Not widely expressed.

Anti-VEGF Reference Antibody (BioMab patent anti-VEGF) - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

Anti-VEGF Reference Antibody (BioMab patent anti-VEGF) - Images

Anti-VEGF Reference Antibody (BioMab patent anti-VEGF) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90%